Status:
COMPLETED
T-cell Based Immunotherapy for of Melanoma
Lead Sponsor:
Inge Marie Svane
Conditions:
Melanoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The aim of this study is to investigate the toxicity and clinical response of therapy with tumor infiltrating lymphocytes as treatment for advanced melanoma. Patient will receive a single treatment c...
Eligibility Criteria
Inclusion
- Patients with histological proven skin derived progressive metastatic or locally advanced malignant melanoma. Further inclusion criteria: Performance Status 0 to 1, surgical available metastasis, at least one measurable lesion, acceptable CBC and blood chemistry results. Acceptable organ functions.
Exclusion
- Patients with a history of any other malignancies less than five years ago. Brain metastases. Other significant illness including severe allergy, asthma, DM, angina pectoris, congestive heart failure, chronic infections, or active autoimmune disease. Treatment with immune suppressive drugs, experimental drugs, or antineoplastic drugs.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00937625
Start Date
June 1 2009
End Date
January 1 2015
Last Update
August 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Oncology, Copenhagen University Hospital, Herlev
Herlev, Denmark, 2730